An Ex Vivo Choroid Sprouting Assay of Ocular Microvascular Angiogenesis
August 6th, 2020
5.5K views
This protocol presents choroid sprouting assay, an ex vivo model of microvascular proliferation. This assay can be used to assess pathways involved in proliferating choroidal micro vessels and assess drug treatments using wild type and genetically modified mouse tissue.
Overview
This protocol presents a choroid sprouting assay as an ex vivo model for studying microvascular proliferation, specifically in relation to choroidal angiogenesis and neovascular age-related macular degeneration (AMD). The assay enables the evaluation of pathways involved in choroidal micro vessel proliferation and the assessment of drug treatments using both wild type and genetically modified mouse tissues.
Key Study Components
Research Area
- Choroidal angiogenesis
- Age-related macular degeneration (AMD)
- Microvascular behavior
Background
- Importance of choroidal angiogenesis in eye diseases
- Ex vivo models complementing in vivo studies
- Genetically modified mouse models for enhanced insights
Methods Used
- Choroid sprouting assay
- Use of mouse tissues from wild type and genetically modified strains
- Microscopy for observing choroidal sprouting
Main Results
- The assay allows reproducible measurements of choroidal sprouting across multiple days
- Loss of FFAR4 in knockout mice increased choroidal vascular growth compared to wild type
- Treatment with FFAR4 agonist reduced choroidal sprouting area in knockout mice
Conclusions
- The study demonstrates the assay's efficacy in evaluating anti-angiogenic potential of pharmacological compounds
- It highlights the role of specific signaling pathways in choroidal neovascularization
Frequently Asked Questions
What is the choroid sprouting assay used for?
It is used to study microvascular proliferation and evaluate potential treatments for neovascular AMD.
How does the assay utilize genetically modified mice?
The assay assesses the effects of specific genetic modifications on choroidal vascular growth.
What are the key findings regarding FFAR4?
FFAR4 knockout mice showed increased choroidal sprouting, while FFAR4 agonist treatment reduced it.
How reproducible is the choroid sprouting assay?
The assay has been shown to produce consistent results for choroidal sprouting over multiple trials.
What roles do choroidal micro vessels play in eye health?
Choroidal micro vessels are crucial for retinal health and their proliferation is linked to eye diseases such as AMD.
What methodologies complement the choroid sprouting assay?
In vivo studies and molecular techniques offer additional insights into microvascular behaviors.
Can this assay assist in drug development?
Yes, it enables screening of compounds that may serve as potential treatments for AMD.
Executive Industry Relevance
The ex vivo choroid sprouting assay provides a reproducible model for evaluating choroidal microvascular proliferation, directly relevant to neovascular age-related macular degeneration (AMD) drug discovery. It enables mechanistic de-risking of angiogenic pathways using wild-type and genetically modified mouse tissues, supporting target validation and lead identification in ophthalmology pipelines. The assay bridges discovery biology and preclinical assessment by quantifying sprouting dynamics in a physiologically relevant tissue explant system.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Interrogates therapeutic hypotheses by measuring choroidal sprouting in response to genetic or pharmacological modulation of angiogenic pathways.
- Operational Value: Enables functional validation of targets like FFAR4 in a multicellular tissue context including endothelium, macrophages, pericytes, and RPE.
- Predictive Value: Supports portfolio triage by quantifying dose-dependent effects of compounds on microvascular sprouting over time.
Screening & Assay Development
- Scientific Value: Generates quantitative, imaging-based readouts of sprouting area that reflect microvascular network formation under controlled conditions.
- Operational Value: Uses standardized explant plating in growth-factor-reduced BME with defined medium change schedules to ensure reproducibility across experiments.
- Scalability: Compatible with 24-well plate format and semi-automated ImageJ analysis for medium-to-high throughput compound screening.
Translational & Preclinical Research
- Scientific Value: Maintains native choroid-RPE-scleral architecture, preserving cell-cell interactions critical for modeling pathophysiological angiogenesis.
- Operational Value: Allows direct comparison of wild-type and knockout tissues (e.g., FFAR4) to isolate genetic contributions to sprouting phenotypes.
- Predictive Value: Enables assessment of agonist/antagonist effects on sprouting, providing preclinical evidence for pathway modulation.
Pipeline & Workflow Integration
The assay fits within the ophthalmology discovery continuum from target validation through lead optimization to preclinical efficacy testing, particularly for anti-angiogenic strategies in AMD.
- Discovery Biology: Supports hypothesis testing of angiogenic regulators by quantifying sprouting changes in response to pathway inhibition or activation.
- Screening: Delivers reproducible, quantitative sprouting metrics that enable rank-ordering of compound effects in a tissue-based format.
- Analytics: Provides time-resolved, area-based measurements (e.g., day 3 to day 6) that support kinetic analysis of microvascular responses.
- Translational Research: Uses disease-relevant explants to model choroidal neovascularization, facilitating extrapolation to in vivo AMD models.
- Enterprise Reuse: Establishes a standardized, reusable platform for evaluating multiple compounds or genetic models across projects.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity by linking genetic or pharmacological perturbations to quantifiable sprouting outcomes in a native tissue context.
- Operational Value: Ensures reproducibility through standardized tissue isolation, BME plating, medium change, and imaging protocols.
- Strategic Value: Improves go/no-go decisions by providing early, tissue-based evidence of anti-angiogenic activity before in vivo testing.
- Portfolio Impact: Enables risk-adjusted prioritization of compounds based on dose-response and genetic validation data.
Implementation Considerations
- Requires expertise in murine tissue dissection and explant isolation under sterile conditions.
- Dependent on access to growth-factor-reduced basement membrane extract (BME) and phase-contrast microscopy.
- Necessitates standardized image analysis workflows (e.g., ImageJ macro) for consistent sprouting quantification.
- Must account for variability in explant size and tissue viability when interpreting sprouting metrics.
- Limited to murine tissue; species differences may affect translatability to human choroidal biology.
Biopharma FAQs
Why does quantifying choroid sprouting area matter for target validation?
Quantifying sprouting area provides a direct, measurable readout of microvascular proliferation, enabling objective assessment of how genetic or pharmacological modulation affects angiogenic pathways in a tissue-relevant context.
How does isolating the choroid-RPE-scleral explant support discovery pipeline goals?
Isolating the intact explant preserves native cell-cell interactions between endothelium, macrophages, pericytes, and RPE, which are critical for modeling pathophysiological angiogenesis and avoiding artifacts from isolated cell cultures.
What do time-lapse measurements of sprouting area enable in preclinical evaluation?
Tracking sprouting area from day 3 to day 6 captures the dynamic progression of microvascular outgrowth, allowing researchers to assess both the rate and magnitude of angiogenic responses to compounds or genetic modifications.
Why are replication requirements important for cross-functional collaboration in this assay?
Reproducible sprouting measurements across independent experiments ensure that observed effects are robust and not due to technical variability, enabling confident data sharing between discovery, preclinical, and translational teams.
What statistical analysis capabilities are needed before implementing this assay in a screening campaign?
The assay requires basic quantitative analysis of sprouting area data (e.g., mean, variance, statistical significance testing) to compare conditions such as wild-type vs. knockout or treated vs. untreated groups, supporting data-driven decision-making.
